Although a previous report showed that LRP8 expression was higher in ER−/HER2− (our TNBC group) compared to ER+/HER2− (our LA group) tumors,21 a complete analysis of all breast cancer subtypes allows us to consider LRP8 as a relevant therapeutic target for both ER−/HER2+ and TNBC subtypes. This evidence concerns the gene ESR1 and breast carcinoma.